From Fighter Jet to Biotech: FSI's New Director Signals Strategic Shift

TABER, ALBERTA – August 31, 2026 – In a move that signals a significant enhancement of its scientific and strategic capabilities, environmental technology firm Flexible Solutions International, Inc. (FSI) today announced the appointment of Dr. Kim Reid to its Board of Directors and Audit Committee. The appointment of Dr. Reid, a process development scientist with a remarkable past as a Royal Canadian Air Force fighter pilot, comes as the company navigates a key transition, marked by the retirement of nearly thirty-year veteran director John Bientjes.

While board reshuffles are routine in corporate life, this particular appointment warrants a closer look. Dr. Reid brings a unique and potent combination of expertise in cutting-edge bio-manufacturing and leadership forged in high-stakes military operations. Her arrival suggests that Flexible Solutions International is not merely filling a seat, but strategically positioning itself for a future increasingly rooted in advanced biological sciences and regulated markets.

A Strategic Pivot Towards Advanced Bio-Manufacturing

Flexible Solutions International has built its reputation on a foundation of environmental technology, specializing in biodegradable polymers like thermal polyaspartate (TPA) for industries ranging from oil extraction to agriculture. However, recent strategic moves indicate a deliberate expansion into higher-value, science-intensive sectors. The company has been increasing its presence in the food and nutrition supplement manufacturing markets, a shift underscored by its 2022 FDA food-grade approval for its Peru, Illinois plant.

This pivot is proving timely. While recent financial reports show a decrease in sales tied to the volatile oil and gas industry, the company has noted a corresponding increase in demand for its food-grade products. This trend highlights the strategic importance of diversifying into more stable and scientifically driven markets. It is within this context that Dr. Reid's appointment appears most impactful.

Her current work at the Ottawa Hospital Research Institute involves leading a technology transfer team to scale the production of mRNA-LNP cancer vaccines for GMP (Good Manufacturing Practice) bio-manufacturing. This experience is directly applicable to FSI's new ventures. The food and nutrition supplement industry is governed by stringent quality control and regulatory standards, areas where GMP expertise is not just beneficial, but essential. Dr. Reid's deep knowledge of upstream and downstream process development, quality assurance, and regulated clean-room procedures provides the board with invaluable insight as it oversees the expansion of this new business vertical.

"Her experience will allow her to contribute to scientific and board discussions, particularly where technology, innovation, risk, regulated environments, evidence-based decision-making and organizational leadership intersect," the company noted in its announcement. This statement points directly to the strategic value FSI places on her ability to bridge the gap between complex science and corporate governance.

From the Cockpit to the Cutting Edge of Science

Dr. Reid's professional journey is anything but conventional. Before earning a PhD in Biology and becoming a leader in mRNA research, she served with distinction in the Royal Canadian Air Force. As an officer and fighter pilot, she flew the CT-114 Tutor, CF-5 Freedom Fighter, and the CF-18 Hornet. Notably, she was the third woman to fly fighter aircraft in Canada and the first to become operationally qualified for both NORAD and NATO combat missions.

This background in high-performance aviation instills a unique skill set: unparalleled risk assessment, rapid decision-making under extreme pressure, and a deep understanding of complex technological systems. These are qualities that translate powerfully to the corporate boardroom, especially for a company navigating the risks and opportunities of technological innovation and new market entry. Her military career was defined by strategic planning and disciplined execution, attributes that are critical for guiding a company's long-term growth.

After her military service, Dr. Reid embarked on an equally impressive scientific career. Armed with an MSc in Experimental Pathology and a PhD in Biology, she has published research in prestigious peer-reviewed journals and now stands at the forefront of one of biotechnology's most exciting fields. Her work with mRNA and lipid nanoparticle (LNP) delivery systems—the same technology that powered the revolutionary COVID-19 vaccines—places her at the cutting edge of modern biologics. As founder of the Expert Talk Series for the Society for RNA Therapeutics, she is not just a participant but a leader in the global biotech community.

Evolving Governance and a New Era of Oversight

The appointment of Dr. Reid is part of a broader leadership evolution at Flexible Solutions International. The departure of John Bientjes, who also served as Audit Committee Chair, marks the end of an era and the loss of nearly three decades of institutional knowledge. In his place, long-time committee member David Fynn has been appointed Audit Committee Chair, a move that ensures continuity and stability in the company’s crucial financial oversight functions.

Dr. Reid’s placement on the Audit Committee is particularly noteworthy. While her financial acumen will be developed, her inclusion brings a different kind of auditing capability to the committee. For a technology company investing heavily in R&D and entering scientifically complex fields, the ability to properly assess technological risk, validate R&D expenditures, and understand the nuances of regulatory compliance in areas like GMP manufacturing is paramount. Dr. Reid provides a level of scientific and regulatory diligence that complements the traditional financial expertise of an audit committee, creating a more robust oversight body.

This move enhances the board's cognitive diversity—the blending of different backgrounds, experiences, and problem-solving approaches. By adding a director with deep scientific and operational leadership credentials, FSI is better equipped to challenge assumptions, vet new strategies, and make more resilient, forward-looking decisions. It reflects a modern approach to corporate governance where the board's composition mirrors the strategic challenges and opportunities the company faces.

The Synergy of Polymers and Molecular Biology

At first glance, FSI’s core business of biodegradable polymers and Dr. Reid’s expertise in mRNA vaccines may seem worlds apart. However, the underlying synergy lies in the shared principles of advanced manufacturing, molecular science, and creating functional products from biological or chemical building blocks. FSI’s TPA biopolymers are derived from the amino acid L-aspartic, and their efficacy depends on precise chemical synthesis and application.

Dr. Reid’s expertise could influence FSI’s innovation pipeline in several ways. Her understanding of molecular biology could inform the development of next-generation biopolymers with enhanced properties or new functional ingredients for the company's nutrition supplement lines. Furthermore, her familiarity with advanced delivery systems like LNPs, while used for genetic material, could inspire novel approaches for delivering FSI’s crop enhancement chemicals or nutritional ingredients more effectively.

By bringing Dr. Reid onto its board, Flexible Solutions International is making a clear statement about its future. The company is investing not just in new markets, but in the foundational scientific expertise required to lead in them. Her appointment provides the board with the vision to see around the corner of technological change and the credibility to guide the company's transformation from an environmental products firm into a diversified technology leader with a serious stake in the future of biotechnology.